Cost-of-illness attributable to smoking: an overview of systematic reviews
e202609047
DOI:
https://doi.org/10.67113/resp.v100i1.1635Keywords:
Cost of disease, Smoking, Systematic review, Tobacco useAbstract
BACKGROUND // Tobacco use constitutes a major global public health problem. The objective of this study was to conduct an overview of reviews on the cost-of-illness attributable to tobacco use, provide a map of the available evidence, identify sources of methodological heterogeneity, assess the quality of the studies, and formulate recommendations for future research.
METHODS // An overview of systematic reviews on tobacco cost-of-illness studies was conducted. Searches were performed in PubMed/MEDLINE, EMBASE, and Google Scholar (from January 1990 to June 2025). Results were synthesized narratively. The degree of overlap among primary studies was calculated, and the methodological quality of the systematic reviews was assessed using AMSTAR 2 and CiCERO.
RESULTS // Six systematic reviews (published between 1999 and 2020) encompassing 143 primary studies were included, with slight overlap among them. The cost-of-illness attributable to tobacco was estimated primarily in actively exposed populations, at the national level and on an annual basis, using prevalence-based approaches and considering multiple diseases, with emphasis on direct healthcare costs. Social costs of up to US$1.44 trillion worldwide (2012) were identified. All systematic reviews were rated as critically low according to AMSTAR 2.
CONCLUSIONS // Although most reviews identify a substantial economic impact of tobacco-attributable disease, comparability between estimation methods is low, and the methodological quality of systematic reviews still has room for improvement.
PROTOCOL REGISTRATION // Open Science Framework: https://osf.io/5trhm/
Downloads
References
1. Tobacco and its environmental impact: an overview. Geneva: World Health Organization; 2017. Disponible en: https://iris.who.int/bitstream/handle/10665/255574/9789241512497-eng.pdf?sequence=1 (acceso 22 de mayo de 2025).
2. Zafeiridou M, Hopkinson NS, Voulvoulis N. Cigarette Smoking: An Assessment of Tobacco’s Global Environmental Footprint Across Its Entire Supply Chain. Environ Sci Technol. 2018 Aug 7;52(15):8087-8094. doi: https://doi.org/10.1021/acs.est.8b01533
3. Beutel M, Harmon T, Novotny T, Mock J, Gilmore M et al. A Review of Environmental Pollution from the Use and Disposal of Cigarettes and Electronic Cigarettes: Contaminants, Sources, and Impacts. Sustainability. 2021, 13, 12994. https://doi.org/10.3390/su132312994
4. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. Geneva: World Health Organization; 2013. Disponible en: https://iris.who.int/bitstream/handle/10665/94384/9789241506236_eng.pdf?sequence=1 (acceso 22 de mayo de 2025).
5. Plan de acción sobre la prevención y el control de las enfermedades no transmisibles 2025-2030. Washington, D.C., 2025. Disponible en: CD62/8 - Plan de acción sobre la prevención y el control de las enfermedades no transmisibles 2025-2030 - OPS/OMS | Organización Panamericana de la Salud (acceso 3 de mayo de 2026).
6. WHO global report on trends in prevalence of tobacco use 2000-2025, third edition. Geneva: World Health Organization; 2019. Disponible en: https://iris.who.int/bitstream/handle/10665/330221/9789240000032-eng.pdf (acceso 22 de mayo de 2025).
7. Eliminating Tobacco-Related Disease and Death: Addressing Disparities—A Report of the Surgeon General. Washington: Department of Health and Human Services; 2024. Disponible en: https://www.hhs.gov/sites/default/files/2024-sgr-tobacco-related-health-disparities-full-report.pdf (acceso 22 de mayo de 2025).
8. GBD 2021 Tobacco Forecasting Collaborators. Forecasting the effects of smoking prevalence scenarios on years of life lost and life expectancy from 2022 to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Public Health. 2024;9(10):e729-e744. doi: https://doi.org/10.1016/S2468-2667(24)00166-X
9. The Tobacco Atlas. Challenge deaths. 2022. Disponible en: https://tobaccoatlas.org/challenges/deaths/ (acceso 29 de junio de 2025).
10. Flor LS, Anderson JA, Ahmad N, Aravkin A, Carr S, Dai X et al. Health effects associated with exposure to secondhand smoke: a Burden of Proof study. Nat Med. 2024;30(1):149-167. doi: https://doi.org/10.1038/s41591-023-02743-4
11. Matt GE, Quintana PJ, Destaillats H, Gundel LA, Sleiman M et al. Thirdhand tobacco smoke: emerging evidence and arguments for a multidisciplinary research agenda. Environ Health Perspect. 2011 Sep;119(9):1218-1226. doi: https://doi.org/10.1289/ehp.1103500
12. Jacob P 3rd, Benowitz NL, Destaillats H, Gundel L, Hang B et al. Thirdhand Smoke: New Evidence, Challenges, and Future Directions. Chem Res Toxicol. 2017 Jan 17;30(1):270-294. doi: https://doi.org/10.1021/acs.chemrestox.6b00343
13. Lovelina Francis D, Sampoornam Pape Reddy S. The silent assassin: Third hand smoking. J Glob Health. 2022;12:03079. doi: https://doi.org/10.7189/jogh.12.03079
14. Prokhorov AV, Winickoff JP, Ahluwalia JS, Ossip-Klein D, Tanski S, Lando HA et al. Youth tobacco use: a global perspective for child health care clinicians. Pediatrics. 2006;118(3):e890-903. doi: https://doi.org/10.1542/peds.2005-0810
15. Xi B, Liang Y, Liu Y, Yan Y, Zhao M et al. Tobacco use and second-hand smoke exposure in young adolescents aged 12-15 years: data from 68 low-income and middle-income countries. Lancet Glob Health. 2016;4(11):e795-e805. doi: https://doi.org/10.1016/S2214-109X(16)30187-5
16. Allen L, Williams J, Townsend N, Mikkelsen B, Roberts N et al. Socioeconomic status and non-communicable disease behavioural risk factors in low-income and lower-middle-income countries: a systematic review. The Lancet Global Health. 2017;5(3). 277-289. doi: https://doi.org/10.1016/S2214-109X(17)30058-X
17. Convenio marco de la OMS para el control del tabaco. Ginebra: Organización Mundial de la Salud; 2003. Disponible en: https://iris.who.int/bitstream/handle/10665/42813/9243591010.pdf (acceso 29 de junio de 2025).
18. Estrategia mundial para acelerar el control del tabaco: promover el desarrollo sostenible mediante la aplicación del CMCT (Convenio marco para el control del tabaco) de la OMS 2019-2025. Compendio de indicadores para la Estrategia Mundial para Acelerar el Control del Tabaco. Enero de 2020 (actualizado en mayo de 2023). Disponible en: 232706-global-strategy-indicator-compendium-15-november-2023-track-changes-sp(1).pdf (acceso 4 de mayo de 2026).
19. Rey-Brandariz J, Pérez-Ríos M, Santiago-Pérez MI, Varela-Lema L, Giraldo-Osorio A, Mourino N, Ruano-Ravina A. Smoking-attributable mortality in Spain: A systematic review. Adicciones. 2023;35(2):185-196. English, Spanish. doi: https://doi.org/10.20882/adicciones.1619
20. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982;60(3):429-662.
21. Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29(8):653-671. doi: https://doi.org/10.2165/11588380-000000000-00000
22. Economics of tobacco toolkit: assessment of the economic costs of smoking. Geneva: World Health Organization; 2011. Disponible en: https://iris.who.int/bitstream/handle/10665/44596/9789241501576_eng.pdf?sequence=1 (acceso 29 de junio de 2025).
23. The Economics of Tobacco and Tobacco Control. National Cancer Institute Tobacco Control Monograph 21. NIH Publication No. 16-CA-8029A. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; and Geneva, CH: World Health Organization; 2016. Disponible en: https://cancercontrol.cancer.gov/sites/default/files/2020-06/m21_complete.pdf (acceso 22 de mayo de 2025).
24. Warner KE, Hodgson TA, Carroll CE. Medical costs of smoking in the United States: estimates, their validity, and their implications. Tob Control. 1999;8(3):290-300. doi: https://doi.org/10.1136/tc.8.3.290
25. John RM, Sinha P, Munish VG, Tullu FT. Economic Costs of Diseases and Deaths Attributable to Tobacco Use in India, 2017-2018. Nicotine Tob Res. 2021. 22;23(2):294-301. doi: https://doi.org/10.1093/ntr/ntaa154
26. Goodchild M, Nargis N, Tursan d’Espaignet E. Global economic cost of smoking-attributable diseases. Tob Control. 2018;27(1):58-64. doi: https://doi.org/10.1136/tobaccocontrol-2016-053305
27. Pichón-Riviere A, Alcaraz A, Palacios A, Rodríguez B, Reynales-Shigematsu LM, Pinto M et al. The health and economic burden of smoking in 12 Latin American countries and the potential effect of increasing tobacco taxes: an economic modelling study. Lancet Glob Health. 2020;8(10):e1282-e1294. doi: https://doi.org/10.1016/S2214-109X(20)30311-9
28. Nargis N, Hussain AKMG, Asare S, Xue Z, Majmundar A, Bandi P et al. Economic loss attributable to cigarette smoking in the USA: an economic modelling study. Lancet Public Health. 2022;7(10):e834-e843. doi: https://doi.org/10.1016/S2468-2667(22)00202-X
29. Xiong X, Huo Z, Zhou Y, Bishai DM, Grépin KA, Clarke PM et al. Economic costs attributable to modifiable risk factors: an analysis of 24 million urban residents in China. BMC Med. 2024;22(1):549. doi: https://doi.org/10.1186/s12916-024-03772-7
30. A study on liability and the health costs of smoking Updated final report. Bruxelles: European Comission, Directorate-General for Health and Food Safety; 2012. Disponible en: https://health.ec.europa.eu/publications/study-liability-and-health-costs-smoking_en (acceso 22 de mayo de 2025).
31. Max W. The financial impact of smoking on health-related costs: a review of the literature. Am J Health Promot. 2001;15(5):321-331. doi: https://doi.org/10.4278/0890-1171-15.5.321
32. Reynales-Shigematsu LM. Costos de atención médica de las enfermedades atribuibles al consumo de tabaco en América: revisión de la literatura. Salud Publica Mex. 2006;48 Suppl 1:S190-200. doi: https://doi.org/10.1590/s0036-36342006000700023
33. Ekpu VU, Brown AK. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence. Tob Use Insights. 2015;8:1-35. doi: https://doi.org/10.4137/TUI.S15628
34. Feirman SP, Glasser AM, Teplitskaya L, Holtgrave DR, Abrams DB, Niaura RS et al. Medical costs and quality-adjusted life years associated with smoking: a systematic review. BMC Public Health. 2016;16:646. doi: https://doi.org/10.1186/s12889-016-3319-z
35. Rezaei S, Akbari Sari A, Arab M, Majdzadeh R, Mohammad Poorasl A. Economic burden of smoking: a systematic review of direct and indirect costs. Med J Islam Repub Iran. 2016;30:397.
36. Makate M, Whetton S, Tait RJ, Dey T, Scollo M, Banks E et al. Tobacco Cost of Illness Studies: A Systematic Review. Nicotine Tob Res. 2020;22(4):458-465. doi: https://doi.org/10.1093/ntr/ntz038
37. Shi L, Zhong L, Cai Y. Economic burden of smoking-attributable diseases in China: A systematic review. Tob Induc Dis. 2020;18:42. doi: https://doi.org/10.18332/tid/120102
38. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13(3):132-140. doi: https://doi.org/10.1097/XEB.0000000000000055
39. Fusar-Poli P, Joaquim R. Ten simple rules for conducting umbrella reviews. Evid Based Mental Health. 2018:21(3):100-195.
40. Gates M, Gates A, Guitard S, Pollock M, Hartling L. Guidance for overviews of reviews continues to accumulate, but important challenges remain: a scoping review. Syst Rev. 2020;9(1):254. doi: https://doi.org/10.1186/s13643-020-01509-0
41. Belbasis L, Bellou V, Ioannidis JPA. Conducting umbrella reviews. BMJ Med. 2022;1(1):e000071. doi: https://doi.org/10.1136/bmjmed-2021-000071
42. Choi G, Hyun K. Introduction to Umbrella Reviews as a Useful Evidence-Based Practice. J Lipid Atheroscler. 2023;12(1):3-11. doi: https://doi.org/10.12997/jla.2023.12.1.3
43. Liu C, Zhou D, Xu W et al. Umbrella Reviews: Concepts, Methodological Frameworks, and Step-by-Step Implementation. Journal of Evidence-Based Medicine. 2025;18(4):1-17. doi: https://doi.org/10.1111/jebm.700921
44. Abdellatif M, Dadam MN, Vu NT et al. A step-by-step guide for conducting an umbrella review. Trop Med Health. 2025;53(134):1-9. doi: https://doi.org/10.1186/s41182-025-00764-y
45. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. doi: https://doi.org/10.1136/bmj.g7647
46. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. doi: https://doi.org/10.1186/s13643-021-01626-4
47. Mulrow CD. The medical review article: state of the science. Ann Intern Med. 1987;106(3):485-488. doi: https://doi.org/10.7326/0003-4819-106-3-485
48. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126(5):376-380. doi: https://doi.org/10.7326/0003-4819-126-5-199703010-00006
49. Vedula S, Mahendraratnam N, Rutkow L, Kaufmann, Rosman L, Twose C et al. A snowballing technique to ensure comprehensiveness of search for systematic reviews: a case study. Poster presentation at the 19th Cochrane Colloquium; 2011 Oct 19-22; Madrid, Spain [abstract]. Cochrane methodology register. Disponible en: https://cmr.cochrane.org/?CRGReportID=16646 (acceso 28 de junio de 2025).
50. Aluko P, Graybill E, Craig D, Henderson C, Drummond M, CF Wilson E et al. Chapter 20: economic evidence 2023. Disponible en: https://training.cochrane.org/handbook/current/chapter-20 (acceso 28 de junio de 2025).
51. National Library of Medicine. Search strategy used to create the PubMed systematic reviews filter. Disponible en: https://www.nlm.nih.gov/bsd/pubmed_subsets/sysreviews_strategy.html (acceso 28 de junio de 2025).
52. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40-46. doi: https://doi.org/10.1016/j.jclinepi.2016.01.021
53. Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67(4):368-375. doi: https://doi.org/10.1016/j.jclinepi.2013.11.007
54. Pérez-Bracchiglione J, Meza N, Bangdiwala SI, Niño de Guzmán E, Urrútia G, Bonfill X, Madrid E. Graphical Representation of Overlap for OVErviews: GROOVE tool. Res Synth Methods. 2022;13(3):381-388. doi: https://doi.org/10.1002/jrsm.1557
55. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. doi: https://doi.org/10.1136/bmj.j4008
56. Mandrik OL, Severens JLH, Bardach A, Ghabri S, Hamel C, Mathes T et al. Goldhaber-Fiebert JD. Critical Appraisal of Systematic Reviews With Costs and Cost-Effectiveness Outcomes: An ISPOR Good Practices Task Force Report. Value Health. 2021;24(4):463-472. doi: https://doi.org/10.1016/j.jval.2021.01.002
57. Schnitzler L, Roberts TE, Jackson LJ, Paulus ATG, Evers SMAA. A consensus-based checklist for the critical appraisal of cost-of-illness (COI) studies. Int J Technol Assess Health Care. 2023;39(1):e34. doi: https://doi.org/10.1017/S0266462323000193
58. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896-900. doi: https://doi.org/10.1016/s0140-6736(99)04149-5. PMID: 10584742.
59. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-12. doi: https://doi.org/10.1016/j.jclinepi.2009.06.005
60. Comité Nacional de Prevención del Tabaquismo. Encuesta de evaluación del control del tabaquismo sobre costes empresariales y sanitarios. Madrid: Comité Nacional de Prevención de Tabaquismo; 2009.59. Disponible en: https://portal-uat.who.int/fctcapps/sites/default/files/2023-02/spain_annex5_evolution_costs_business_health.pdf (acceso 28 de junio de 2025).
61. Cobacho Tornel MB, López Nicolás A, Ramos Parreño JM. El coste de mortalidad asociado al consumo de tabaco en España. Rev Esp Salud Publica. 2010; 84(3):271-280. doi: https://doi.org/10.1590/s1135-57272010000300005
62. Suárez-Bonel MP, Villaverde-Royo MV, Nerín I, Sanz-Andrés C, Mezquida-Arno J, Córdoba-García R. Health care costs and work absenteeism in smokers: study in an urban community. Arch Bronconeumol. 2015;51(12):615-620. doi: https://doi.org/10.1016/j.arbres.2015.05.001
63. The Tobacco Atlas. Country Factsheets: Spain. Disponible en: https://tobaccoatlas.org/factsheets/spain/ (acceso 29 de junio de 2025).
64. Bakhtiari Aliabad M, Masoudi-Asl I, Abolhallaje M, Jafari M. Building a house on sand: how tobacco use is devouring resources. Addict Health. 2023;15(2):128-135. doi: https://doi.org/10.34172/ahj.2023.1375
65. Sweis NJ, Elfessi ZZ, Rubinstein I, Caskey R. Economic Burden of Self-Reported Tobacco Smoking Compared with Non-Smoking: Systematic Review and Meta-Analysis of Direct Health Care Costs. Adv Ther. 2025;42(10):5134-5147. doi: https://doi.org/10.1007/s12325-025-03318-0
Downloads
Additional Files
- FIGURA 1 (Español (España))
- TABLA 1 (Español (España))
- TABLA 2 (a) (Español (España))
- TABLA 2 (b) (Español (España))
- TABLA 2 (c) (Español (España))
- TABLA 2 (d) (Español (España))
- TABLA 3 (a) (Español (España))
- TABLA 3 (b) (Español (España))
- TABLA 4 (Español (España))
- TABLA 5 (a) (Español (España))
- TABLA 5 (b) (Español (España))
- TABLA 5 (c) (Español (España))
- ANEXO I (a) (Español (España))
- ANEXO I (b) (Español (España))
- ANEXO I (c) (Español (España))
- ANEXO I (d) (Español (España))
- ANEXO II (Español (España))
- ANEXO III (Español (España))
- ANEXO IV (a) (Español (España))
- ANEXO IV (b) (Español (España))
- ANEXO V (Español (España))
- ANEXO VI (Español (España))
- ANEXO VII (Español (España))
- ANEXO VIII (Español (España))
- ANEXO IX (Español (España))
Published
Versions
- 2026-09-10 (2)
- 2026-09-09 (1)
How to Cite
License
Copyright (c) 2026 Scarlett Holguín Galvis, Paula Martín-García, Ferrán Catalá-López
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
![¿Cómo evaluar para la RESP? [PARA REVISORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-revisores-0eaa113abcbc4fc554c7c6c7840ca4c6.jpg)
![¿Cómo recibir avisos sobre nuevos artículos de la RESP? [PARA LECTORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-lectores-aa689338e95aab07df45b4b0d583188f.jpg)
